Distal Esophageal Spasm (DES)

Overview of the Condition

DES manifests as uncoordinated, often simultaneous contractions in the distal two-thirds of the esophagus, leading to impaired bolus transit. The disorder is notable for its episodic nature and variable symptomatology, which can mimic cardiac pathology.

Epidemiology

• Incidence and Prevalence: DES is rare, with an estimated prevalence of 2–9% among symptomatic patients undergoing esophageal motility testing. Population-based data suggest an incidence of approximately 1 per 100,000 individuals per year.
• Age and Gender Distribution: The median age at diagnosis is around 60 years, with a higher prevalence in women. No significant racial predilection has been reported.

Etiology

The precise etiology of DES remains incompletely understood. Proposed mechanisms include:

• Imbalance of Neural Pathways: Dysfunction in the inhibitory (nitric oxide-mediated) and excitatory (cholinergic) neural pathways of the myenteric plexus is central to pathogenesis.
• Nitric Oxide Deficiency: Experimental models demonstrate that nitric oxide (NO) deficiency induces simultaneous esophageal contractions, while NO repletion reverses this effect.
• Medication Effects: Chronic opioid use is associated with increased risk of DES, likely due to modulation of NO pathways. Psychotropic medications and psychiatric comorbidities are also implicated.
• Other Factors: Gastroesophageal reflux disease (GERD) and, rarely, food allergies or intolerances may contribute.

Pathophysiology

DES is characterized by premature, high-amplitude contractions in the distal esophagus with preserved lower esophageal sphincter (LES) relaxation. The key pathophysiological feature is a reduction in contractile latency (the interval of deglutitive inhibition), resulting in simultaneous or rapidly propagated contractions. This is attributed to impaired inhibitory neurotransmission, particularly involving NO, within the esophageal myenteric plexus.

Signs and Symptoms

• Chest Pain: Substernal, squeezing pain often indistinguishable from angina pectoris; may radiate to the back and is frequently triggered by swallowing or emotional stress.
• Dysphagia: Intermittent difficulty swallowing both solids and liquids, often described as a sensation of food sticking in the chest.
• Regurgitation and Heartburn: Less common, but may occur in association with GERD.
• Other Symptoms: Rarely, patients may experience cough, weight loss, or food impaction.

Diagnostics

• High-Resolution Manometry (HRM): Gold standard for diagnosis. Diagnostic criteria (Chicago Classification v3.0) require ≥20% premature contractions (contractile latency <4.5 seconds) with normal LES relaxation.
• Barium Esophagram: May reveal a “corkscrew” or “rosary bead” appearance, but findings are not pathognomonic.
• Endoscopy: Primarily to exclude structural lesions; typically normal in DES.
• Functional Lumen Imaging Probe (FLIP): Provides complementary assessment of esophageal distensibility and motility, especially when HRM findings are equivocal.

Differential Diagnoses

• Achalasia (especially type 3): Distinguished by impaired LES relaxation on HRM.
• Gastroesophageal Reflux Disease (GERD): May coexist or mimic DES symptoms.
• Cardiac Ischemia: Must be excluded in patients presenting with chest pain.
• Other Motility Disorders: Nutcracker esophagus, hypercontractile (Jackhammer) esophagus, and functional chest pain.

Therapeutic Options

Medical Therapy

• Proton Pump Inhibitors (PPIs): For concurrent GERD symptoms.
• Smooth Muscle Relaxants: Nitrates, calcium channel blockers, and phosphodiesterase-5 inhibitors (e.g., sildenafil) may reduce contraction amplitude and frequency, but efficacy is variable and limited by side effects.
• Peppermint Oil: May provide symptomatic relief in some patients.
• Tricyclic Antidepressants: Occasionally used for pain modulation.

Endoscopic and Surgical Interventions

• Botulinum Toxin Injection: Temporarily relieves symptoms by inhibiting acetylcholine release; efficacy is limited to less than one year and repeated injections may complicate future interventions.
• Peroral Endoscopic Myotomy (POEM): Emerging as an effective and safe option for refractory cases, with success rates >80% in specialized centers. Requires expertise and is associated with longer procedure times compared to achalasia.
• Surgical Myotomy: Considered when POEM is unavailable or unsuccessful; rarely performed.

Current State of Research

Recent advances in HRM and FLIP have refined diagnostic criteria and improved differentiation from other motility disorders. Ongoing research focuses on elucidating the molecular mechanisms underlying DES, particularly the role of NO and neural regulation, and on optimizing minimally invasive therapeutic strategies such as POEM.

Summary of Key Recent Studies

• HRM and FLIP: Studies confirm HRM as the diagnostic gold standard, with FLIP providing valuable adjunctive information.
• Pharmacologic Trials: Limited efficacy of smooth muscle relaxants and need for individualized therapy highlighted.
• POEM Outcomes: Retrospective analyses demonstrate high efficacy and safety for POEM in DES, though randomized controlled trials are needed.

Prognostic Factors

• Symptom Severity and Duration: Chronic, severe symptoms may predict poorer response to medical therapy.
• Response to Initial Therapy: Patients refractory to pharmacologic agents may require endoscopic or surgical intervention.
• Comorbidities: Psychiatric and neurologic comorbidities may complicate management and affect prognosis.

Classification Systems

• Chicago Classification (CC) v3.0: Defines DES as ≥20% premature contractions (contractile latency <4.5 seconds) with normal LES relaxation.
• Spectrum of Spastic Motility Disorders: DES is part of a continuum that includes hypercontractile esophagus and type 3 achalasia.

In summary, Distal Esophageal Spasm is a rare, complex motility disorder with variable clinical presentation and challenging management. Diagnosis relies on high-resolution manometry, and treatment is often empirical, with POEM emerging as a promising option for refractory cases. Ongoing research aims to clarify pathophysiology and optimize therapeutic strategies in accordance with current clinical guidelines.

Sources